SRA Wins $100 Million Contract with Department of Defense

SRA International, Inc. (NYSE: SRX), a leading provider of technology and strategic consulting services and solutions to government organizations and commercial clients, today announced that the Department of Defense (DoD) awarded the company a re-compete contract to support the receipt and scientific review of research grant applications for DoD’s Congressionally Directed Medical Research Programs (CDMRP). The contract has a potential total dollar value of $100 million over five years, if all options are exercised.

SRA has provided a vast range of services supporting scientific and technical merit review of the thousands of research grant applications received by the U.S. Army Medical Research and Materiel Command’s (USAMRMC) CDMRP. Research initiatives supported by SRA have included breast, prostate and ovarian cancers; chronic myelogenous leukemia; osteoporosis; neurofibromatosis; tuberous sclerosis complex; autism spectrum disorder, amyotrophic lateral sclerosis, post traumatic stress disorder, traumatic brain injury, prion diseases; and initiatives related to the health and readiness of military personnel.

“CDMRP plays an important role in supporting disease-specific research, and in addressing the issues faced by our military members and their families. SRA fully shares this mission and we are proud that CDMRP will allow us to continue this partnership,” said SRA Health Programs Vice President Paul Nedzbala. “By leveraging our scientific expertise, information technology and administrative support, SRA has been able to provide an unsurpassed level of service to CDMRP. Our team is focused on CDMRP’s mission as we make meaningful contributions to advances in important areas of biomedical research.”

A centerpiece of SRA’s support for CDMRP (and other scientific peer review clients) is its proprietary Program and Peer Review Management Information System (P2RMIS®) application, which supports the scientific review process, including online application evaluation and scoring, meeting and travel support, document management and information reporting. P2RMIS also houses a database of thousands of scientific professionals who have served on peer review panels and/or who are available to serve.

CDMRP holds a highly respected position in the research community for its emphasis on investment strategies that fill unique gaps and seek innovative ideas with the capacity to effect transformational change in the treatment of targeted diseases and conditions. CDMRP is rare among federal grant makers because of its emphasis on meaningful consumer engagement, disease-specific approach, pursuit of innovative research and two-tiered review process that results in funding decisions based on technical merit and programmatic relevance.

About SRA International, Inc.

SRA and its subsidiaries are dedicated to solving complex problems of global significance for government organizations and commercial clients serving the national security, civil government and global health markets. Founded in 1978, the company and its subsidiaries have expertise in such areas as air surveillance and air traffic management; contract research organization (CRO) services; cyber security; disaster response planning; enterprise resource planning; environmental strategies; IT systems, infrastructure and managed services; logistics; public health preparedness; public safety; strategic management consulting; systems engineering; and wireless integration.

SRA and its subsidiaries employ more than 7,000 employees serving clients from its headquarters in Fairfax, Va., and offices around the world. For additional information on SRA, please visit www.sra.com.

Any statements in this press release about future expectations, plans, and prospects for SRA, including statements about the estimated value of the contract and work to be performed, and other statements containing the words “estimates,” “believes,” “anticipates,” “plans,” “expects,” “will,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements. In addition, the forward-looking statements included in this press release represent our views as of August 10, 2010. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to August 10, 2010.

Sra (NYSE:SRX)
Historical Stock Chart
From Jun 2024 to Jul 2024